Algocell’s machine learning platform simulates and optimizes biological processes, helping companies scale from lab experiments to commercial production more efficiently. The technology is designed to address persistent challenges in biomanufacturing, such as inconsistent yields, high costs, and unpredictable cell behavior in large-scale bioreactors.
The funding will support team expansion, enhancement of the platform’s predictive capabilities, and the launch of commercial pilot programs across industries including cultivated meat, precision fermentation, biopharma, cosmetics, and biofuels.
The round was led by Good Company VC, with participation from angel investors. The round also included a non-dilutive grant from the Israel Innovation Authority.